ClinicalTrials.gg
RecruitingNCT06510764Updated Mar 16, 2026

A Trial of Chinese Traditional Medicine Combining With Intradermal Acupuncture for Treating Precocious Puberty

A Phase 3 interventional study of intradermal needles and Ziyinxiehuo Granules of traditional Chinese Medicine in Precocious Puberty, Treatment and Alternative Medicine, sponsored by Children's Hospital of Fudan University. Recruiting at 2 sites in China. Open to female participants aged 4 Years to 9 Years. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Children's Hospital of Fudan University · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.
Phase
Phase 3
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
4 Years to 9 Years
Sex
Female
01

Study summary

A randomized controlled study will be conducted to evaluate the therapeutic effect of traditional Chinese medicine and acupoints stimulation on children with idiopathic precocious puberty.

Read the detailed description

Traditional Chinese medicine is effective for precocious puberty which is mild or moderate, but not effective for the one that is severe and rapidly progressing. Acupuncture can effectively regulate sex hormone levels and ovarian function, promote ovulation, and have therapeutic effect for polycystic ovary syndrome and irregular menstruation. Studies have shown that acupuncture and auricular point compression stimulation is effective for premature thelarche, yet there are few studies on idiopathic precocious puberty. Clinical evidence is still needed to support whether acupuncture point stimulation combined with traditional Chinese Medicine herbs can enhance the effect and prevent the progression into severe or rapidly progressing precocious puberty, hence the study is to be carried out.

02

Conditions studied

  • Precocious Puberty
  • Treatment
  • Alternative Medicine
  • Acupuncture

Browse trials for

03

In context

Puberty, Precocious

75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.

This study's planned enrollment of 170 is above the median of 64 across 47 interventional studies indexed under Puberty, Precocious.

Browse Puberty, Precocious studies →

Lead sponsor

Children's Hospital of Fudan University is the lead sponsor of 268 studies on the registry; 95 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 9 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Girls are diagnosed as Idiopathic precocious puberty, and their age of onset ≤7.5years;
  • Tanner stages of breast in female patients ≤ Tanner III stage, diameters of mammillary nucleus ≤ 3cm; •B-type ultrasonography: the volume of uterus≥ 3ml, the volume of ovary≥1.5ml, the diameter of follicle≥4mm;
  • Bone age: compared the chronological age, the bone age is less than 1 year and the bone age \<10 years old;
  • No GnRH analogs or Sex hormones were administrated in the past; and All above are needed at the same time.

Exclusion criteria

Exclusion Criteria:

  • Precocity caused by the central nervous system organic diseases;
  • Precocious precocity caused by congenital hypothyroidism, congenital adrenal hyperplasia, adrenal tumor and ovarian or testicular neoplasms as well as McCune-Albright syndrome, etc;
  • Precocious precocity with a family history of diseases such as tumor, leukemia, diabetes, systemic lupus erythematous;
  • Pseudo sexual precocity and partial precocious puberty.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
170 participants (estimated)

Study arms

  • Experimental
    Traditional Chinese Medicine+acupuncture

    Subjects in this group will be treated with traditional Chinese medicine and intradermal acupuncture point stimulation for 6 months.

    Other: intradermal needles · Drug: Ziyinxiehuo Granules of traditional Chinese Medicine

  • Active comparator
    Traditional Chinese Medicine

    Subjects in this group will be treated withTraditional Chinese Medicine for 6 months.

    Drug: Ziyinxiehuo Granules of traditional Chinese Medicine

Interventions

  • Otherintradermal needles

    Disposable intradermal needles will be used for acupoint stimulation and Tai Chong, Taixi, Sanyinjiao, Hegu as well as Yanglingquan are chosen for acupuncture point. Acupuncture point pressure will last for 10 minutes each time, three times per day, and the intradermal needles will be changed every 2 days.

  • DrugZiyinxiehuo Granules of traditional Chinese Medicine

    Ziyinxiehuo Granules of traditional Chinese Medicine which includes shengdi 15g, xuanshen 9g, zexie 9g, zhimu9g, huangbai 9g, zhiguiban 9g, maiya 15g, tiandong 9g, zhigancao 9g,and will be administered after dissolved, 1package every time, 2 times per day after a meal.

    Also known as: traditional Chinese Medicine for nourishing Yin and purging fire

06

What researchers measure

Primary outcomes

  1. The percentage of subjects' mammary nucleus minification or disappearance at the third month.

    The diameters of mammary nucleus will be measured with rulers along the median line of the breast at baseline,the third month and the sixth month. The subject numbers of mammary nucleus minification or disappearance at third month will be recorded. The percentage=the subject numbers of mammary nucleus minification or disappearance /total subject numbers in this group ×100%.

    Time frame: from baseline to the third month.

Secondary outcomes

  1. the change in bone age/the change in chronological age after six months

    The bone age will be measured with X-ray and evaluated with G-P Atlas method at baseline and the sixth month. the change in bone age= bone age after six months-bone age at baseline, the change in chronological age is six months.

    Time frame: from baseline to the sixth month

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06510764
Responsible party
Sponsor
First posted
Jul 19, 2024
Start date
Sep 15, 2024
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Mar 16, 2026

Study contacts

Han Xinghui, Master
Contact
1055952886@qq.com
021-64931219
Sun Yanyan, Master
principal investigator · Children's Hospital of Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion